CVR: 39119374
Previous names: Embark Biotech IvS, Embark Biotech ApS
Novo Nordisk Research Center Gladsaxe ApS is a Danish company of the type Anpartsselskab based in Bagsværd, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Embark Biotech ApS and Embark Biotech IvS. The management consists of Rikke Ryttergaard Andersen. The company is owned by NOVO NORDISK A/S. The company has 7 employees. In 2025, the company reported a gross profit of DKK -1,000 and a net result of DKK 48,000 compared with DKK 6,174,000 the year before. Equity amounted to DKK 807,000.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at udføre forskning, udvikling og støtte kliniske forsøg af farmaceutiske produkter og at markedsføre, promovere, sælge og distribuere farmaceutiske og medicinske produkter samt enhver anden aktivitet i forbindelse hermed. Endvidere er selskabets formål at understøtte Novo Nordisk A/S' farmaceutiske aktiviteter. Selskabet bestræber sig på at udføre sine aktiviteter på en økonomisk, miljømæssig og socialt ansvarlig måde.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | -1 t. | 48 t. | 833 t. | 807 t. | 0 | |
| 2024 | -38 t. | 6.2 mio. | 8.5 mio. | 6.8 mio. | 0 | |
| 2023 | - | 395.5 mio. | 517 mio. | 405.6 mio. | 2 | |
| 2022 | 379 t. | -8.8 mio. | 7.8 mio. | -5.9 mio. | 4 | |
| 2021 | 0 | -6.2 mio. | 10.7 mio. | 2.9 mio. | 3 | |
| 2020 | 10.7 mio. | 3.2 mio. | 11.7 mio. | 9.5 mio. | 5 | |
| 2019 | 25.6 mio. | 14.4 mio. | 28.2 mio. | 18.3 mio. | 5 | |
| 2018 | 14.9 mio. | 9.8 mio. | - | 52 t. | 1 |
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreCompared to 1.042 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2025. Gross profit came to DKK -1,000, and the net result was DKK 48,000.
As of May 29, 2026, EY Godkendt Revisionspartnerselskab has stepped down as auditor of Novo Nordisk Research Center Gladsaxe ApS.
As of December 3, 2025, Rikke Ryttergaard Andersen is registered as adm. dir. of Novo Nordisk Research Center Gladsaxe ApS.
As of December 3, 2025, Trine Haastrup has stepped down as director of Novo Nordisk Research Center Gladsaxe ApS.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2024. Gross profit came to DKK -38,000, and the net result was DKK 6,174,000.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2023. The net result was DKK 395,475,000.
As of August 29, 2023, Peter Bøggild has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Kristine Aachmann Bethe has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Casper Tind Hansen has left the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Klaus Christian Schollmeier has left the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Trine Haastrup is registered as director of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Casper Tind Hansen has stepped down as adm. dir. of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Jakob Bondo Hansen has stepped down as director of Novo Nordisk Research Center Gladsaxe ApS.
On August 29, 2023, the company changed its name from Embark Biotech ApS to Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, NOVO NORDISK A/S is registered as an owner of Novo Nordisk Research Center Gladsaxe ApS with an ownership share of 100%.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2022. Gross profit came to DKK 379,438, and the net result was DKK -8,830,214.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2021. Gross profit came to DKK 0, and the net result was DKK -6,196,311.
As of August 9, 2021, Casper Tind Hansen has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 9, 2021, Klaus Christian Schollmeier has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 9, 2021, Jakob Bondo Hansen is registered as director of Novo Nordisk Research Center Gladsaxe ApS.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2020. Gross profit came to DKK 10,676,598, and the net result was DKK 3,185,064.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2019. Gross profit came to DKK 25,623,833, and the net result was DKK 14,426,111.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2018. Gross profit came to DKK 14,947,235, and the net result was DKK 9,820,500.
As of May 21, 2019, EY Godkendt Revisionspartnerselskab has been appointed auditor of Novo Nordisk Research Center Gladsaxe ApS.
On August 15, 2018, the company changed its name from Embark Biotech IvS to Embark Biotech ApS.
As of November 28, 2017, Casper Tind Hansen is registered as adm. dir. of Novo Nordisk Research Center Gladsaxe ApS.
Novo Nordisk Research Center Gladsaxe ApS was founded on November 28, 2017.
Companies in the same industry and area
CVR 45943062
CVR 41093447
CVR 37918806
CVR 46282744
CVR 44805472
companydata.dk